TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04133948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domatinostat
Description: Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domatinostat
Description: Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domatinostat
Description: Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses nivolumab 240 mg q3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses nivolumab 240 mg q3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses nivolumab 240 mg q3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 2 courses nivolumab 240 mg q3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 2 courses ipilimumab 80 mg q3weeks
Study: NCT02783170

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tetanus, Diphtheria, and Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tetanus, Diphtheria, and Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2016-2017 Quadrivalent Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2016-2017 Quadrivalent Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2017-2018 Quadrivalent Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Study: NCT01797393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention:  Air assisted water injection.
Description: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
Study: NCT02344329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topical wound dressing
Description: Topical Wound Dressing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amnion Allograft
Description: Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual wound care
Description: assessment, wound cleansing, debridement, moist wound environment, and off-loading

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual wound care
Description: assessment, wound cleansing, debridement, moist wound environment, and off-loading
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously
Study: NCT02178904

Intervention type: PROCEDURE
Intervention: CT and stress test
Description: Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
Study: NCT01198002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered Subcutaneously (SC)
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20mg or 1000 mg or other strengths as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: 20mg or other strength as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: 20mg or other strength as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: 20mg or other strength as locally available given intravenously
Study: NCT01198002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2127399
Description: Administered Subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Q2W
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Q4W
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a background therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a background therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate is a background therapy.
Study: NCT03760445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: 25mg capsules given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine/daunorubicin
Description: 100mg/44mg or other strength as locally available given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: 100mg delayed release tablet or other strength as locally available given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2mg/mL oral solution or in other strength as locally available
Study: NCT02654951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Feedback
Description: A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Feedback
Description: A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible.
Study: NCT04600830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
Study: NCT02144727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 distal subtotal gastrectomy
Description: D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D1+ distal subtotal gastrectomy
Description: D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
Study: NCT03104946

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus

Intervention type: DIAGNOSTIC_TEST
Intervention: Mental Development Index;Auditory Brainstem Response;okineticnystagmus
Description: mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
Study: NCT01173497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INIPARIB + irinotecan
Description: 21 day cycle
Study: NCT00964964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected s.c. (under the skin) three times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec injected s.c. (under the skin) once daily for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo injected s.c. (under the skin) four times weekly
Study: NCT03063333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coping-oriented hypnosis
Description: Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neutral hypnosis
Description: Hypnosis using neutral suggestions plus current treatment
Study: NCT01503593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium Phosphate, Calcium Sulphate
Description: 1cc of Calcium Phosphate and 1cc of Calcium Sulphate
Study: NCT02495792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback Sensor
Description: Tibia accelerometer strapped to distal tibia to detect tibial shock
Study: NCT02101385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genomically Directed Monotherapy
Description: Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:

Intervention type: OTHER
Group type: OTHER
Intervention: Observation/Standard Therapy
Description: Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
Study: NCT03480308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
Study: NCT05355467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Historical Data
Description: Historical Data
Study: NCT03480308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine
Study: NCT00529958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar Tendon
Description: Patellar Tendon autograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Tendon
Description: Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-Bundle
Description: Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
Study: NCT03759431

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vocal-cord Radiotherapy
Description: Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Complete Larynx Radiotherapy
Description: Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
Study: NCT02766465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: A:~Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A:~Fludarabine dose will be 35 mg/m\^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m\^2).~C:~Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-ATG
Description: A:~r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplant
Description: A,B,C:~Day 0 is the day of transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: A:~Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.~C:~Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: A:~Methotrexate will be administered intravenously on day+1 at 15mg/m\^2, day+3 at 10mg/m\^2, day+6 at 10mg/m\^2, and day+11 at 10mg/m\^2.~C:~Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Continue to receive standard of care treatment per patient's SCD physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: B:~Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3~C:~Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total Body Irradiation 300 cGY on Day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ \>50%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: C:~Melphalan 140 mg/m2 IV dose will be given on Day -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 5 μg/kg/day continue until neutrophil engraftment.
Study: NCT03425669

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stochastic Vestibular Stimulation
Description: Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stochastic Vestibular Stimulation
Description: Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
Study: NCT00669279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR
Description: Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
Study: NCT02817802

Intervention type: DEVICE
Intervention: Magmaris
Description: PCI (Magmaris)
Study: NCT04083105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intranasal midazolam will be given after nitrous oxide administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intranasal midazolam will be given after nitrous oxide administration.
Study: NCT00066014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Overdenture Treatment
Description: All overdenture treatment modalities were provided to each subject using a crossover design.
Study: NCT01719705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ninety minutes before surgery, the parturients receive two identical placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300 mg group
Description: Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150 mg group
Description: Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule